[1]李林法.18F-FDG分子符合成像非肿瘤性摄取与对策[J].国际放射医学核医学杂志,2002,26(5):205-209.
　LI Lin-fa.Nonmalignant accumulations and its decision of 18F-FDG molecular coincidence imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(5):205-209.
点击复制

18F-FDG分子符合成像非肿瘤性摄取与对策(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
26
期数:
2002年第5期
页码:
205-209
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Nonmalignant accumulations and its decision of 18F-FDG molecular coincidence imaging
作者:
李林法
310003 浙江, 浙江大学医学院附属第一医院核医学科
Author(s):
LI Lin-fa
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Hangzhou 310003, China
关键词:
18F-氟代脱氧葡萄糖; 生理性摄取; 良性病变; 肿瘤; 鉴别诊断
Keywords:
2-18F-fluoro-2-deoxy-D-glucose; physiological accumulations; benign pathologic; neoplasms; differential
分类号:
R817.4
摘要:
18F-FDG显像可以提供肿瘤细胞生物特性信息,且大多数肿瘤具有靶/非靶高比率的特性,目前已有效地应用于全身各种肿瘤。但是,除肿瘤外,正常组织及一些良性病变也可摄取18F-FDG,这些非肿瘤摄取常可造成假阳性或者掩盖恶性肿瘤灶。通过阐述各种非肿瘤性摄取,包括生理性、良性、炎症性摄取的特点以及鉴别点,图像融合、双时相显像应用到非肿瘤性摄取的鉴别,认为同机图像融合是鉴别肿瘤性摄取与生理性摄取首选方法。
Abstract:
18FF-FDG imaging can provide information about the biologic characteristics of malignant cells,and has high target-to-nontarget ratios in most common neoplasms,recently has been successfully used in various neoplasms throughout the body.However 18F-FDG is a non specific tracer,and it has been found to accumulate at sites of normal tissue and some benign pathologic.This uptake of nonmalignant tissue may be misinterpreted as a false positive result or mask a nearby malignant lesion.We describe various nonmalignant uptake’s characteristic and differential including physiologic,benign,infection and inflammation,image fusion,dual time point imaging be applied to distinguish nonmalignant accumulations.Con sider the combined imaging fusion is the first optimal modality in distinguish m alignant accumulations from physiologic.

参考文献/References:

[1] Shreve PD, Anzai Y, Wahl RL. Pitfall in oncologic diagnosis with FDG PET imaging:physiologic and benign variants[J].Radiographics, 1999, 19(1):61-77.
[2] Brigid GA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography:normal variations, pitfalls, and technical considerations[J]. Am J Roentgenol, 1997,169:1675-1680.
[3] Miraldi F, Vesselle H, Faulhaber PF, et al. Elimination of artifactual accumulation of FDO in PET imaging of colorectal cancer[J]. Clin Nucl Med, 1998, 23:3-7.
[4] Conti PS, Durshi JM, Singer PA, et ah Incidence of thyroid gland uptake of F-18 FDG in cancer patients[J]. Radiology,1997, 205:220.
[5] Bar-Shalom R. Muscle uptake of 18-fluorine fluoro deoxyglucose[J]. Semin Nucl Med, 2000, 30(4):306-309.
[6] Engel H, Steinert H, Buck A, et al. Whole-body PET:Physiological and artifactual fluorodeoxyglucose accumulations[J]. J Nucl Med, 1996, 37:441-446.
[7] Mossberg KA, Mommession JI, Taegtmeyer H. Skeletal muscle glucose uptake during short-term contractile activity in vivo:effect of prior contractions[J]. Metabolism, 1993, 42:1609-1616.
[8] Kostakoglu L, Wong JCH, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG[J]. J Nucl Med, 1996, 37:1771-1773.
[9] Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine 18-FDG:effect on oral diazepam[J]. J Nucl Med, 1996, 37:1127-1129.
[10] 赵军.18F-FDG PET诊断肿瘤应考虑的几个问题[J].国外医学·放射医学核医学分册,1999,23(6):241-245.
[11] Sugawara Y, Fisher SJ, Zasadny KR, et al. Pre-clinic and clinic studies of bone marrow uptake of fluorine-18-fluo-rodeoxyglucose with or without granulocyte colony-stimulating factor during chemotheraphy[J]. J Clin Oncol, 1998,16:173-180.
[12] Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum:mormal anatomy, variants,pathologic conditions, and strategies to avoid diagnostic pitfalls[J]. Radiographics, 1998, 18:805-823.
[13] Kosuda S, Fisher S, Kison PV, et al. Uptake of 2-deoxy-2-18F-fluoro-D-glucose in normal testis:retrospective PET study and animal experiment[J]. Ann Nucl Med, 1997, 11:195-199.
[14] Chander S, Meltzer CC, Mccook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography[J]. Clin Nucl Med, 2002, 27(1), 22-24.
[15] Meyer M, Gast T, Raja S, et al. Increased F-18 FDG accumulation in an acute fracture[J]. Clin Nucl Med, 1994, 19:13-14.
[16] Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sacoidosis[J]. J Nucl Med,1994, 35:1647-1649.
[17] Strauss LG. Fluorine-18-deoxyglucose and false-positive results:a major problem in the diagnostics of oncological patients[J]. Eur J Nucl Med, 1996, 23:1409-1415.
[18] Kim SK, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET[J]. Radiographics, 1999, 19:61-77.
[19] Yun MJ, Jang SY, Cucchiara A, et al. 18F-FDG uptake in the large arteries:Acorrelation study with the atherogenic risk factors[J]. Semin Nucl Med, 2002, 32(1):70-76.
[20] Paul G, Kluetz BS, Carolyn CM, et al. Combined PET/CT imaging in oncology impact on patient management[J]. Clin Positronimag, 2000, 3(6):223-230.
[21] Inagaki H, Kato T, Tadokoro M, et al. Interactive fusion of three-dimensional imagines of upper abdominal CT and FDG PET with no body surface markers[J]. Radiat Med, 1999, 17:155-163.
[22] Zhuang HM, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation[J]. Semin Nucl Med, 2002, 32(1):47-59.
[23] Mamede M, Saga T, Ishimori T, et al. Differential uptake of F-18-FDG in experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of steroid pretreatment on tumor uptake[J]. J Nucl Med, 2001,42:1172.
[24] Zhuang HM, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes[J]. J Nucl Med, 2001, 42(9):1412-1417.
[25] Matties A, Hickeson M, Cuchiara A, et al. Dual time point 18F-FDG PET for the evaluation of puimonary nodules[J]. J Nucl Med, 2002, 43(7):871-875.
[26] Nakamoto Y, Higashi T, Sakahara H, et al. Delayed FDGPET scan for the differentiation between malignant and benign lesions[J]. J Nucl Med, 1999, 40:247.
[27] Herzog HR, Borner AR, Weckesser M, et al. Delayed scan time for FDG PET in breast cancer[J]. J Nucl Med, 1999,40:140.
[28] Ishizu K, Nakamura S, Shiozaki T, et al. Increasing rate of FDG uptake from early to delayed PET images in lung tumors[J]. J Nucl Med, 2000, 41:76.

相似文献/References:

[1]蔡莉,李彦生.氟代脱氧葡萄糖与氨基酸PET在脑肿瘤中的对比研究[J].国际放射医学核医学杂志,2005,29(1):10.
　CAI Li,LI Yan-sheng.Comparison of 18F-FDG and amino acid PET imaging in brain tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):10.
[2]陈香,赵军.PET-CT在非小细胞肺癌中的应用[J].国际放射医学核医学杂志,2005,29(3):97.
　CHEN Xiang,ZHAO Jun.The application value of PET-CT imaging in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):97.
[3]季仲友.PET-CT中诊断性CT的必要性与临床应用[J].国际放射医学核医学杂志,2005,29(5):197.
　JI Zhong-you.Necessity and clinical application of diagnostic CT in PET-CT scanner[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):197.
[4]陈香,赵军,管一晖.PET-CT常见伪影[J].国际放射医学核医学杂志,2005,29(5):201.
　CHEN Xiang,ZHAO Jun,GUAN Yi-hui.Common artifacts on PET-CT images[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):201.
[5]吴湖炳.18F-氟代脱氧葡萄糖PET-CT在头颈部肿瘤中的应用价值[J].国际放射医学核医学杂志,2005,29(5):205.
　WU Hu-bing.The clinical application value of 18F-FDG PET-CT on the head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):205.
[6]董孟杰,林祥通,赵军.PET-CT在卵巢癌中的临床应用价值[J].国际放射医学核医学杂志,2005,29(5):209.
　DONG Meng-jie,LIN Xiang-tong,ZHAO Jun.The application of PET-CT in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):209.
[7]刘建军,黄钢.18F-氟代脱氧葡萄糖PET和PET-CT在转移性骨肿瘤中的应用研究[J].国际放射医学核医学杂志,2005,29(5):213.
　LIU Jian-jun,HUANG Gang.Application study of 18F-FDG PET and PET-CT on malignant bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):213.
[8]华逢春,管一晖,赵军.18F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用[J].国际放射医学核医学杂志,2005,29(5):216.
　HUA Feng-chun,GUAN Yi-hui,ZHAO Jun.18F-FDG PET and PET-CT imaging in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):216.
[9]黄建敏,付占立,潘莉萍.18F-FDG代谢显像标准摄取值的影响因素[J].国际放射医学核医学杂志,2004,28(1):3.
　HUANG Jian-min,FU Zhan-li,PAN Li-ping.Affect factors of the standardized uptake value for metabolic imaging with 18F-fluorine-2-deoxy-D-glucose[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):3.
[10]董爱生.18F-FDG PET在结直肠癌中的临床应用价值[J].国际放射医学核医学杂志,2004,28(1):12.
　DONG Ai-sheng.The applications of 18F-FDG PET in colorectal carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):12.

备注/Memo

备注/Memo:
收稿日期:2002-08-17。
作者简介:李林法(1965-),男,浙江杭州桐庐人,副主任医师,硕士,主要从事核素肿瘤显像和治疗研究。
更新日期/Last Update: 1900-01-01